ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
162.25
+3.22 (+2.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close159.03
Open157.50
Bid161.86 x 800
Ask162.24 x 1100
Day's Range157.30 - 162.33
52 Week Range69.11 - 164.09
Volume710,211
Avg. Volume880,919
Market Cap18.629B
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-7.98
Earnings DateAug 04, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est155.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Did Hedge Funds Make The Right Call On Alnylam Pharmaceuticals, Inc. (ALNY) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Alnylam Pharmaceuticals, Inc. (ALNY) ?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • Business Wire

    Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle East region, announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.

  • Alnylam Pharma Poised to Shoot Higher
    TheStreet.com

    Alnylam Pharma Poised to Shoot Higher

    The biopharmaceutical company shows bullish charts that signal a breakout to new all-time highs. The charts and indicators are bullish,

  • Reuters

    FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs

    Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.

  • Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
    Business Wire

    Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new data from the open-label extension (OLE) period of the ENVISION Phase 3 study, reinforcing the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, M.D., Ph.D., during a webinar hosted by Alnylam. In an interim analysis of the OLE period, givosiran, which is approved in the U.S. and EU and marketed as GIVLAARI®, demonstrated sustained efficacy and safety through 12 months of treatment, with evidence for potentially improved efficacy over time.

  • GuruFocus.com

    New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19

    GERM offers investors exposure to established providers and ‘unsung heroes’ of biotech and life sciences Continue reading...

  • Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series
    Business Wire

    Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of "RNAi Roundtable" webinars over the coming weeks. The series will offer a range of presentations from Alnylam scientists and program leaders, as well as clinical collaborators, who will review recent progress in many of the Company’s pipeline programs and platform. Each event will be webcast live on the Investors section of the Company’s website at www.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event.

  • Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
    Business Wire

    Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT (1:30 pm ET) via webcast.

  • Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
    Business Wire

    Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal results from the ENVISION Phase 3 study of givosiran, an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), were published online in the New England Journal of Medicine (NEJM). GIVLAARI® (givosiran) was approved by the U.S. Food and Drug Administration for the treatment of adults with AHP in November 2019, marking the first ever approval of a GalNAc-conjugate RNAi therapeutic—a landmark in the advancement of precision genetic medicines. It also received marketing authorization from the European Commission in March 2020 for the treatment of AHP in adults and adolescents aged 12 years and older. The full manuscript, titled "Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria," will appear in the June 11, 2020 issue of NEJM.

  • Alnylam Reports Positive Phase III Results on Lumasarin
    Zacks

    Alnylam Reports Positive Phase III Results on Lumasarin

    Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.

  • Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick
    SmarterAnalyst

    Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick

    Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).PH1 is an ultra-rare orphan disease caused by excessive oxalate production, and elevated urinary oxalate levels are associated with progression to end-stage kidney disease and other systemic complications.The clinical data was presented at a virtual session of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).Lumasiran, an investigational RNAi therapeutic, achieved the primary endpoint with a 53.5% mean reduction in urinary oxalate relative to placebo (p=1.7×10-14) and showed a 65.4% mean reduction in urinary oxalate relative to baseline.All tested study secondary endpoints were met, including the proportion of patients achieving near-normalization (84%) or normalization (52%) of urinary oxalate, compared with 0% in the placebo group.Lumasiran also showed an encouraging safety and tolerability profile, with no serious or severe adverse events (AEs) and with mild injection site reactions as the most common drug-related AE.Based on these results, Alnylam has now filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The FDA has granted a Priority Review for the NDA with a December 3, 2020 action date under the Prescription Drug User Fee Act (PDUFA).In addition, the Marketing Authorisation Application (MAA) for lumasiran has received Accelerated Assessment from the European Medicines Agency (EMA).The study “represents the sixth positive Phase 3 study for an investigational RNAi therapeutic, and we believe it further highlights the transformational potential of this modality as a whole new class of medicines” said Akshay Vaishnaw, President of R&D at Alnylam.“Overall, we think the data is solid, consistent with prior Phase I/II, and we anticipate rapid approval by the December 3rd PDUFA date” RBC Capital analyst Luca Issi told investors following the data release.However the analyst reiterated his Hold rating on the stock with a $150 price target, arguing that ALNY’s trailblazing phase 1 may actually end up providing a clearer path for rival Dicerna Pharma (DRNA)- which has a Strong Buy Street consensus.“We think DRNA is better positioned for PH given: 1) better dosing (fixed vs. weight-based dosing); 2) potential for broader label (can tackle all PH subtypes vs. only PH1); and 3) DRNA may capitalize on ALNY’s heavy lifting on building disease awareness” Issi explained. He has a buy rating on Dicerna with a $35 price target (73% upside potential).Analysts currently hold a cautiously optimistic Moderate Buy consensus on Alnylam with a $157 average price target (23% upside potential). The stock is currently trading up 11% year-to-date. (See ALNY stock analysis on TipRanks)Related News: AbbVie’s Rinvoq Beats Bristol-Myers’ Orencia In New Rheumatoid Arthritis Data Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed More recent articles from Smarter Analyst: * Eli Lilly Leaps 13% On Positive Results For Its Verzenio Breast Cancer Therapy * Billionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks * iQIYI Pops 35% In Pre-Market On Report Tencent Seeks To Buy Big Stake * First Horizon, IberiaBank Get U.S. Regulatory Nod For Merger

  • Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
    Business Wire

    Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The clinical data were presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held as a virtual event on June 6-9.

  • Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report?
    Zacks

    Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish
    Insider Monkey

    Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program
    Business Wire

    Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that seven patient advocacy groups will receive supportive funding as part of the company’s second annual Advocacy for Impact grants program. The global competitive grants program aims to inspire patient advocacy groups to develop solutions that address critical unmet needs among the hereditary transthyretin-mediated (hATTR) amyloidosis, acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1) rare disease communities.

  • Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
    Business Wire

    Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET. Lumasiran is an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The clinical data will be presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held June 6-9 as a virtual event.

  • Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
    Zacks

    Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA

    Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.

  • Alnylam to Webcast Presentations at Upcoming June Investor Conferences
    Business Wire

    Alnylam to Webcast Presentations at Upcoming June Investor Conferences

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

  • Thomson Reuters StreetEvents

    Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT

    Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1
    Business Wire

    Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The FDA also granted Priority Review for the NDA, a designation for medicines that have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease, with the goal of FDA taking action within six months compared to 10 months under standard review.

  • Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?

    Is (ALNY) Outperforming Other Medical Stocks This Year?

  • Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020
    Business Wire

    Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from the Global Open-Label Extension (OLE) study of ONPATTRO® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults, at the European Academy of Neurology (EAN) Virtual Congress. In addition, interim results were presented from a Phase 3b trial evaluating treatment with patisiran in patients with hATTR amyloidosis with disease progression after receiving an orthotopic liver transplant (post-OLT).

  • Is Alnylam Pharmaceuticals a Buy?
    Motley Fool

    Is Alnylam Pharmaceuticals a Buy?

    Alnylam Pharmaceuticals (NASDAQ: ALNY) has been a phenomenal biotech stock. The company had its initial public offering in 2004. Shares are now 22 times more valuable than they were 16 years ago. That's an incredible stock performance.

  • GlobeNewswire

    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

    SAN FRANCISCO, May 12, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.

  • How Alnylam (ALNY) Stock Stands Out in a Strong Industry
    Zacks

    How Alnylam (ALNY) Stock Stands Out in a Strong Industry

    Alnylam (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.